Inverseon Announces Positive Phase IIa Asthma Study
SAN FRANCISCO, January 29, 2008 /PRNewswire/ -- Inverseon, Inc. (http://www.inverseon.com) announces the publication of a positive phase IIa clinical trial in asthma.
In the article by Hanania et al., in Pulmonary Pharmacology & Therapeutics, vol. 21, (2008), pp. 134-141, entitled, "The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot study," mild asthmatics were treated for 9 weeks. All subjects tolerated the drug, and 8 of 10 subjects experienced a clinically meaningful, dose-related, reduction in airway hyper-responsiveness.
"To our knowledge, this is the first peer-reviewed publication of a clinical trial testing a beta-blocker for the treatment of asthma," commented Richard Bond, PhD, Scientific Founder of Inverseon. "These results lay the groundwork for continuing safety and efficacy studies for a drug that is normally withheld from asthmatics. A similar story played out 10 years ago in congestive heart failure where certain blocker drugs that were once contraindicated are now on the market as the best drugs we have ever had at decreasing mortality in heart failure."
"From receptor theory to animal data and now to clinical data the Inverseon approach is very consistent. In our animal asthma models chronic dosing of beta inverse agonists -- which are a subset of beta blockers -- resulted in up-regulation of lung beta receptors, while reducing inflammation and airway hyper-responsiveness. The fact that we are seeing some of these same changes in human asthmatic subjects is exciting and suggests we may have a way to counteract some of the negative aspects of long-acting beta-agonists and steroids when used in combination with INV102. The data also supports Inverseon's reformulation program for oral controlled-release INV102," commented William J. Garner, MD, Chairman of Inverseon.
About Inverseon, Inc.
Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects "Paradoxical Pharmacology," based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon's website at http://www.inverseon.com.
This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.
Contact: William J. Garner, MD http://www.inverseon.com (212) firstname.lastname@example.org
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
CONTACT: William J. Garner, MD of Inverseon, Inc., +1-212-222-1188, email@example.com
Web site: http://www.inverseon.com/
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: January 2008